Comparative Pharmacology
Head-to-head clinical analysis: ENBREL versus RENFLEXIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENBREL versus RENFLEXIS.
ENBREL vs RENFLEXIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tumor necrosis factor (TNF) inhibitor; etanercept is a dimeric fusion protein consisting of the extracellular ligand-binding portion of human TNF receptor p75 linked to the Fc portion of human IgG1. It binds to soluble and membrane-bound TNF, thereby blocking TNF-mediated inflammatory responses.
Renflexis (infliximab-abda) is a chimeric monoclonal antibody that binds with high affinity to tumor necrosis factor alpha (TNFα), neutralizing its pro-inflammatory activity. It inhibits TNFα binding to its receptors (TNFR1 and TNFR2), reducing inflammatory cell migration, cytokine production, and tissue damage.
50 mg subcutaneous injection once weekly
5 mg/kg intravenously over at least 2 hours at 0, 2, and 6 weeks, then every 8 weeks.
None Documented
None Documented
Approximately 102 hours (range 68–170 hours) after subcutaneous administration in adults; prolonged in elderly and patients with renal impairment; supports every 2-week dosing.
Terminal elimination half-life approximately 18-21 days (mean ~20 days) in patients with rheumatoid arthritis; supports every-8-week dosing interval.
Renal: negligible; Biliary/Fecal: not significantly eliminated; primarily degraded via proteolysis into amino acids.
Primarily eliminated via reticuloendothelial system degradation; renal excretion accounts for <1% of dose as unchanged drug; no significant biliary or fecal excretion.
Category C
Category C
TNF-alpha Inhibitor
TNF-alpha Inhibitor